[Venlafaxine extended release and alcohol dependence]

Area of Science:

• Pharmacology
• Addiction Medicine
• Clinical Psychiatry

Context:

• Substance dependence disorders pose significant public health challenges.
• Detoxification is a critical first step in addiction treatment.
• Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI).

Purpose:

• To evaluate the efficacy of venlafaxine extended release (ER) as an adjunct therapy in patients undergoing alcohol or cocaine detoxification.
• To assess the impact of venlafaxine ER on alcohol use, social functioning, medical status, and psychiatric symptoms during detoxification.

Summary:

• This observational study involved 55 adult patients with alcohol and/or cocaine dependence undergoing inpatient detoxification.
• Patients received venlafaxine ER (75-225 mg/day) for six months.
• Significant improvements were observed in EuropASI scores for alcohol use, family/social relations, medical status, and psychiatric status (P < 0.01).
• Visual Analog Scale (VAS) scores for alcohol craving also decreased significantly from baseline to endpoint (P < 0.001).

Impact:

• The findings suggest venlafaxine ER may be a beneficial co-adjuvant therapy for alcohol-dependent patients during detoxification.
• Results indicate potential for improved treatment outcomes in addiction management.
• Larger, placebo-controlled trials are recommended to validate these preliminary findings and establish definitive efficacy.